Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Tbh if the initial data is as good as we all hope I don't think the market will have a clue how to value us, so I think there will be a delay where the SP goes up but will give chance for well researched investers to put more money in, albeit at a higher price, but with significantly less risk. From Feb onwards is where we'll see fireworks. Like when novacyt went from £2.50 to £12 over several months. I'd be quite happy with that. Just no court case though please, Al.
I'd like to see a licence deal within next 3 - 6 months, if only to raise the SP and prevent a cheap TO.
I emailed Al in comic sans (so a hostile takeover) offering £50 and an expired family voucher to West Midlands safari Park but haven't heard back.
Twatter is correct, the delay is him considering the offer. I'll keep you updated.
Saw these mentioned on twitter on an avacta feed, I remember coming across them before when reading about affimers, antibodies and aptamers etc.
Basically these guess have developed DARPins, another alternative to antibodies and from 2 minutes of thorough research, similar qualities to affimers, and have been used in clinical trials already.
In fact, their own pipeline which to my untrained eye looks very similar to Tmac, has completed phase 1, no MTD found, no significant side effects. Their drug mp0310 uses DARPins to target the tumour and ensure immune cells only activate there, based on FAP, and their MP0317 also similar. They're preclin in a couple of others, and licenced some drugs out.
Awesome. What interests me is the share price. Its lower than that of Avacta (although I saw theirs crash around May), yet has more advanced drugs in clinic with as good a safety profile you could hope, along with demonstrating that the tumour shrank in a stage 3 patient with I think breast or liver cancer.
What gives? I can't see any Moln themed share chats either, do the US not give much of a sheet about small biotech?
I'm in novacyt (unfortunately) , will be back to 60p in a week or two. I'm holding on in the desperate hope the court case will be settled in March in their favour so I can get out with some of my cash. Will lump it here it its still sub 1.50
Excellent. Just another £3 to go. Great news for thermo and roche, not sure if nova will get any crumbs from the cake, that involves our sales team doing some actual work and finding someone capable of reading a contract.
Cabozantinib, their prized possession, has nasty side effects, not much better than platinum based chemo.
https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/cabozantinib
Even so, last year that drug alone made $1.4bn in revenues (mcap around $bn). Similar figures to the current dox market, which ava could massively expand on. Granted their pipeline is a lot futher on, and established as a proven drug. Ava designed to work along side these types of inhibitors too, so potential in future for clinical trials combining likes of this with precision targetted chemo.
Interesting that the science days mentions fund managers and city analysts ahead of leaders in oncology. Is it that those in the oncology field would already be well aware of progress so far through inner channels, or is it that this is going to be foooooking massive and will make avacta the hottest share to own in 2023?
Creative accounting
Had my eye on this one for a while and is approaching my buy in price, however just seen comments above about dividends are paid net.
I'll be usijg my isa for this as dividend allowance already used up, Im registered for self assessment so is there an option on there to reclaim tax for this (assuming it really is paid net of tax)
AS said 4 planned. Only reason they they'd go for more now rather than move to next phase is if a pharma has agreed / in talks to fund it if first four escalations haven't found a MTD and they want to see how specific the platform is before agreeing final terms to a licence deal or possible take over, all imo. Avacta will have budgeted carefully for each phase and wouldn't just go rogue, and the recent fund raise that was over subscribed could have given additional funds, but they declined. Who turns down cheap money at a pivotal time in development, unless its a drop in the ocean to what might be coming.
I think we'll hear before Xmas what their plans are. Another DE or not, it's exciting.
Isn't medusa just based in a shed in Manchester where some work experience kid updates the website occasionally? Their accounts from 2021 don't make for pretty reading, and they had an average of 8 staff, at a time when covid was in full swing. About the same as a tesco express.
Was hoping that link was dead. Richard Hughes better off sticking to golf.
Impressed with the Xmas toy choices here, in years gone by its been knock off or cheap tat, spotted most of the things our kids have asked for from adverts (mainly YouTube) so good to know the product buyers are on the ball. Local store busy at 10.00 on black Friday.
Crl123 - how can you say the dispute is factored in when no one knows if nova will win the dispute and get back to £2+ or lose and need an emergency fund raise at pennies to keep the lights on for 12 months.
This share is a complete gamble at the moment which is why it's dropping. If Dave was really confident we'd not only win the dispute, but have it resolved in next 3-6 months he'd have stuck around to claim the glory. Getting back to my average of £3.50 is probably impossible short of another pandemic, so its damage limitation for me.
Doesn't really matter what nova RNS product wise, or a £250k contract, only one thing will have a positive effect on the SP and that's successful resolution of the dispute.
You get a lot of stick PI100, and when this happens on the avacta board i usually join in in telling them to FRO as they're utterly clueless deramping t055ers just out to try and irritate posters who are invested in one the UKs most promising companies. In this case though your predictions have been more correct than anyone else on this board, new investors thinking this is a bargain based on mcap and cash in the bank would do well to read your posts. Easily the most inept company I've ever invested in, and I have shares in SYME.
I don't think we'll hear for the next week or two, perhaps longer, even if company have results back now. This is cancer changing news, they aren't going to release a 1 paragraph RNS and be done with it. They'll want to arrange presentations, invite clinical experts to review data, drum up interest (such as recent conference). As part of same news I imagine they'll outline 1b, perhaps identify the best tumour type to target. In fact the longer it takes for them to release to market, the more serious and company changing it is, won't be trivialised with a 'oh BTW it works quite well' RNS. Maybe they're even discussing licence terms behind the scenes.
Take as long you need, Al.
That took me down a Google rabbit hole, Bein.
Had a skim read of this article from March this year
https://www.sciencedirect.com/science/article/pii/S1742706121008266
"Furthermore, 1 of 6 patients treated with L-377,202 at the efficacious dose of 225 mg/m2 exhibited dose-limiting neutropenia"
So far the best they can do with Dox is mild hyperthermia by dunking you in an uncomfortably hot bath.
Why the obsession here with avacta? Nova was a pure covid play, did well and now backfired and haemorrhaging cash due to sloppy management not reading contracts they've signed (I've lost thousands here) , avacta got distracted by covid, spaffed up cash but quickly realised they were on to a loser, but theyre now weeks or even days away from discovering if their cancer targeting precision tech is safe, potentially opening up a drugs pipelines worth billions.